In CNS lesions, ''reactive astrocytes'' form a prominent cellular response. However, the nature of this astrocyte immune activity is not well understood. In order to study astrocytic immune responses to inflammation and injury, we generated mice with conditional deletion of p38a (MAPK14) in GFAP1 astrocytes. We studied the role of p38a signaling in astrocyte immune activation both in vitro and in vivo, and simultaneously examined the effects of astrocyte activation in CNS inflammation. Our results showed that specific subsets of cytokines (TNFa, IL-6) and chemokines (CCL2, CCL4, CXCL1, CXCL2, CXCL10) are critically regulated by p38a signaling in astrocytes. In an in vivo CNS inflammation model of intracerebral injection of LPS, we observed markedly attenuated astrogliosis in conditional GFAPcre p38a 2/2 mice. However, GFAPcre p38a 2/2 mice showed marked upregulation of CCL2, CCL3, CCL4, CXCL2, CXCL10, TNFa, and IL-1b compared to p38afl/fl cohorts, suggesting that in vivo responses to LPS after GFAPcre p38a deletion are complex and involve interactions between multiple cell types. This finding was supported by a prominent increase in macrophage/microglia and neutrophil recruitment in GFAPcre p38a 2/2 mice compared to p38afl/fl controls. Together, these studies provide important insights into the critical role of p38a signaling in astrocyte immune activation.
A strocytes are the most abundant glial cell type in the CNS. They perform essential regulatory functions contributing to the maintenance of CNS homeostasis, including extracellular glutamate uptake 1 , synaptic transmission 4 , and microcirculation regulation 5, 6 . The CNS is a relatively immune privileged compartment due to the lack of lymphatic drainage and unique characteristics of its vasculature. The blood brain barrier (BBB) regulates CNS microcirculation and consists of perivascular astrocytic endfeet constituting the neurovascular unit together with endothelial cells, pericytes and microglia. Disruption of the integrity of the BBB is one of the prominent pathological changes seen after CNS injury, and is induced by complex molecular mechanisms regulated by cytokines, chemokines, nitric oxide, adhesion molecules and matrix metalloproteinases (MMPs) 7, 8 that interact with components of the neurovascular unit. In particular, astrocytes in response to CNS injury exhibit a pathological hallmark termed as ''reactive astrogliosis''. Studies of reactive astrocyte elimination suggest that astroglial scar formation ameliorates widespread tissue damage 9, 10 , but detrimental effects by reactive astrocytes in inhibiting oligodendrocyte progenitor cell (OPC) migration and remyelination have also been reported 11, 12 . Therefore, the outcome of reactive astrogliosis contributing to CNS neuropathology remains controversial. In response to inflammatory stimuli, astrocytes also produce proinflammatory cytokines and chemokines [13] [14] [15] [16] . Studies suggest that astrocyte-derived TNFa and IL-1b exacerbate inflammatory responses by inducing BBB disruption through paracrine effects on endothelial cells [17] [18] [19] . Moreover, astrocytes are also implicated to be a major source of crucial chemokines involved in BBB disruption and leukocyte recruitment during CNS injury 14, 20 . In particular, monocyte chemotaxis induced by CCL2 results in BBB breakdown by the downregulation of endothelial tight junction proteins 21 . CXCL10 promotes T lymphocyte infiltration into the CNS parenchyma 22 , whereas CXCL1 facilitates the transmigration of neutrophils across the BBB 23 . Taken together, studies on reactive astrogliosis and its regulation of immune cell trafficking suggest a significant yet controversial role of astrocytes during CNS inflammatory injury. It remains much debated as to whether immune activation of astrocytes can facilitate or exacerbate the outcome of CNS injury, and the definitive role of astrocytes contributing to CNS neuropathology remains to be determined. The mitogen-activated protein kinase (MAPK) family transduces signals from the cell membrane to the nucleus in response to a wide variety of stimuli 24 . MAPK family members are serine/threonine protein kinases belonging to (1) p38 MAPKs, (2) extracellular signal-related kinases 1 and 2 (ERK1/2), and (3) Jun amino-terminal kinases (JNKs) [25] [26] [27] . p38 MAPK family members (p38a, p38b, p38c and p38d) are involved in cell cycle regulation, apoptosis, cell development, proliferation and inflammatory responses [28] [29] [30] [31] [32] . Among these, p38a is considered to be a central regulator of an inflammatory response in multiple cell types 33, 34 . Downstream substrates of p38a include transcription factors and protein kinases, leading to divergent signaling cascades that dictate cellular responses to stress and inflammation 35 . Pharmacological studies using p38 MAPK inhibitors indicated that astrocytes upregulate TNFa and IL-1b through a p38a-mediated pathway 36, 37 . Through a feedback mechanism, downstream effects of TNFa and IL-1b promote subsequent upregulation of astrocyte-derived chemokines CCL2, CCL5 CXCL2, CXCL8 and CXCL10 15, 38, 39 . Although an essential role of p38a in the astrocyte immune responses has been suggested in in vitro studies using chemical inhibitors 37, 40, 41 , these inhibitors are not particularly specific and can also inhibit p38b and other enzymes. Therefore, the definitive role of p38a in the production of specific cytokines and chemokines in astrocytes has not been examined. Moreover, administration of p38 MAPK inhibitors in vivo also exhibits general therapeutic effects on CNS injury models [42] [43] [44] . However, due to the complexity of the in vivo CNS inflammation involving microglia, astrocytes and infiltrating leukocytes, there is insufficient information with regard to the cell-type specific immune response downstream of p38a signaling. Although astrocytes are capable of performing immunological functions during CNS injury, no studies have delineated the specific role of astrocytic p38a signaling in conditions of in vivo CNS inflammation. To study the p38a-mediated mechanisms in response to in vivo CNS inflammation, we first deleted the p38a gene in GFAP 1 astrocytes in mice. Using this model, we sought to examine p38a-mediated immunological events during astrocytic immune response and define the role of astrocytes in CNS inflammation.
Methods
Animals. Mice with floxed alleles of p38a [B6.129-Mapk14,tm1.2Otsu.] were generated and described previously 45 . Human glial fibrillary acidic protein -cre recombinase expressing mice [hGFAP-Cre; FVB-Tg(GFAP-cre)25Mes/J] as well as the recombination-reporter strain ROSA26-tdTomato(mT)-EGFP(mG) [Gt(ROSA)26-Sortm4(ACTB-tdTomato,-EGFP)Luo/J] were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). All mice were maintained in accordance to the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Experimental protocols used for this study were approved by the Institutional Animal Care and Use Committee at the University of California, Davis.
Generation and genotyping of transgenic p38a
fl/fl and GFAP cre p38a 2/2 mice. Conditional GFAP-specific p38a knockout mice were generated using Cre/loxP recombination system by cross breeding hGFAP-Cre mice (FVB/N background) and p38a-floxed mice (C57BL/6 background). The hGFAP-Cre positive heterozygous p38a-floxed mice were then backcrossed to obtain mice homozygous for p38a (p38a fl/fl ) mice with and without hGFAP-Cre (GFAP cre ). Mice were genotyped using tail tip DNA at weaning. In brief, tail tips were lysed in buffer containing proteinase K and processed for DNA extraction by using QIAamp DNA Mini Kit (Qiagen, Valencia, CA). Purified genomic DNA was subjected to PCR using BiolaseH Taq DNA Polymerase (Bioline, Tauton, MA). The genotypes of p38a fl/fl and GFAP cre p38a 2/2 mice were examined by analyzing two transgenic compositions in genomic DNA, including hGFAP-Cre and the presence of p38a-floxed alleles using specific primers (Table S1 ). Desired genotypes of either p38a fl/fl or GFAP cre p38a 2/2 mice were generated for both in vitro primary culture and in vivo experiments.
Primary culture of astrocytes from p38a fl/fl and GFAP cre p38a 2/2 mice. In order to obtain astrocyte cultures in high purity, we cross bred a double fluorescent Crereporter line, ROSA26-tdTomato(mT)-EGFP(mG) 46 , with hGFAP-Cre mice. After cross breeding, the tdTomato gene flanked by two loxP sites is deleted by Cre-loxP recombination, leading to EGFP expression in specific cell types with activated hGFAP promoter. We used the P2 progeny to generate astrocyte cultures. The primary astrocyte cultures were established from the neonatal cerebral cortex using a method modified from Fasano et al. 47 . In brief, the cortex was dissected and isolated from the diencephalon. Meninges and pia mater were carefully removed from the dorsal and ventral side of the cortex. Cerebral cortex was then separated and made into single cell suspension by gentle trituration followed by sequential passage through 100 mm and 40 mm nylon cell strainers. The resulting cells were then plated on 5% poly-D-lysine coated T75 flasks, and allowed to grow in minimum essential medium without D-valine (US Biologicals, Swampscott, MA) supplemented with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 1% non-essential amino acid solution and 1% penicillin-streptomycin solution (all from Invitrogen, Carlsbad, CA). This mixed glial culture was maintained at 37uC in a humidified incubator with 5% CO 2 for 7-10 days and allowed to reach 90% confluence. Subsequently, loosely adherent microglia and oligodendrocyte progenitor cells were dislodged and removed by mechanical shaking at 275 rpm for 20 hours in an orbital shaker within the incubator. The culture was then incubated in medium containing 50 mM L-leucine methyl ester hydrochloride for 1 hour to completely eliminate residual proliferating microglia 48 . The resulting cultures were then trypsinized, counted and passaged onto cover slips to examine the purity of astrocyte populations under fluorescent microscope. Astrocytes with activated hGFAP promoter will express EGFP-encoded green fluorescence protein on the membrane, whereas other contaminating cell types including microglia, oligodendrocytes, and fibroblasts will show a red fluorescent appearance due to an inactivated hGFAP promoter. The established protocol was then used to generate p38a fl/fl and p38a 2/2 astrocytes derived from p38a fl/fl and GFAP cre p38a
2/2 mice, respectively.
In vitro astrocyte cytokine treatments. To examine the specific responses to interluekin-1b (IL-1b) and lipopolysaccharide (LPS) exposure, p38a fl/fl and p38a
astrocyte were seeded onto 35 mm 6-well plates at a density of 5 3 10 5 cells per well. At . 90% confluence, astrocytes were treated with serum-free MEM medium for 24 hours and then exposed to IL-1b (100 ng/ml; Millipore, Billerica, MA) or LPS (100 ng/ml; Sigma, St. Louis, MO). For cytokine treatment studies, astrocytes were grouped into 3 wells per treatment and treated with either IL-1b for 0, 15, 30, 45, 60, 90 or 120 min, or LPS for 0, 30, 60 or 90 min to examine specific MAPK protein activation using western blot analysis.
To quantify different cytokine and chemokine gene expression, p38a fl/fl and p38a 2/2 astrocytes were seeded in 100 mm dishes at a density of 2.5 3 10 6 cells per dish. Astrocytes were kept in culture for 2-4 days to reach ,90% confluence, and changed into serum-free MEM medium the day before cytokine treatment. To study the role of p38a signaling in astrocytic immune responses, we subjected astrocytes to IL-1b (30 ng/ml), interferon-c (100 ng/ml, Millipore, Billerica, MA) or LPS (100 ng/ ml) treatments for 0, 2, 4 or 6 hours, and examined immune gene expression using a real-time quantitative reverse transcriptase-polymerase chain reaction (qPCR) approach.
Western blot analysis. Astrocytes treated with either IL-1b or LPS for indicative time points were grouped from 3 wells of 6-well plates and lysed by RIPA buffer supplemented with protease and phosphatase inhibitors (Roche, Indianapolis, IN). Cell lysates were resuspended by adding sample buffer containing 0.5 M Tris, sodium dodecyl sulphate (SDS), glycerol, dithiothreitol (DTT) and bromophenol blue. Samples were then boiled for 5 min, spun down to collect condensation and subjected to 10% SDS-PAGE. Gels were transferred to a PVDF membrane and immunoblotted with the following primary antibodies (from Cell Signaling Technology, Danvers, MA): phospho-p38 MAPK (Thr180/Tyr182) (Catalog # 4511), p38 MAPK (Catalog # 9212), phospho-SAPK/JNK (Thr183/Tyr185) (Catalog # 4668), SAPK/JNK (Catalog # 9295), phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204) (Catalog # 9106), p44/42 MAPK (Erk1/2) (Catalog # 4695), MAPKAPK2 (MAP Kinase-activated protein kinase-2, Thr222) (Catalog # 3316), and a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA) (Catalog # sc-8035). In brief, PVDF membranes were blocked with 5% non-fat dry milk in Tris-buffered saline Tween 20 (TBST) for 1 hour at room temperature, and then incubated with primary antibodies in blocking solution for 16 hours at 4uC. After three washes in TBST, membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Piscataway, NJ) for 1 hour at room temperature. Bound secondary antibodies were visualized by chemiluminescence using Pierce ECL Western Blotting Substrate (Thermo Scientific, Barrington, IL).
Stereotaxic intracerebral LPS injection. Intracerebral injections of LPS into the cerebral cortex of p38a fl/fl and GFAP cre p38a 2/2 mice were performed in a stereotaxic alignment system (David Kopf Instruments, Tujunga, CA). In brief, twelve-week old mice were anesthetized with isofluorane and positioned in the stereotaxic frame. A 0.2 mm hole was drilled in the skull of the right hemisphere at coordinates of 2 mm anterior to bregma and 1.5 mm lateral to the midline. Injection of LPS (2 mg in 2 ml saline) was performed using a glass micropipette at a depth of 1.8 mm below the duramater using the nanoject II (Drummond Scientific, Broomall, PA). After 6, 12 or 24 hours mice were transcardially perfused with PBS and a 2 mm cylindrical core sample of tissue was collected from the injection site for mRNA extraction. For immunohistochemistry, PBS perfusion was followed by 4% formaldehyde and the whole brain was processed for histology. Immunohistochemical staining for infiltrating cell quantification.
Immunocytochemistry was performed to quantify infiltrating lymphocytes in the CNS parenchyma of p38a fl/fl and GFAP cre p38a 2/2 mice 24 hours after intracerebral LPS injection. Mice were anesthetized with intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), and then transcardially perfused with PBS followed by 4% parafomaldehyde. Brains were postfixed in 4% parafomaldehyde overnight before sectioning into 25 mm sections on a cryostat. In brief, frozen sections were incubated in blocking solution (5% goat serum with 0.03% Triton X-100) at room temperature for 1 hour, and then incubated overnight at 4uC with primary antibodies (anti-rat Iba1, Wako, Richmond, VA; anti-mouse Ly6G, BD Bioscience, San Jose, CA) prepared in the same blocking solution. Sections were washed in PBS, and then incubated in the species-appropriate fluorescent-conjugated secondary antibodies. Sections were counterstained with DAPI, and then coverslipped using Prolong Gold Anti-Fade reagent (Invitrogen). Stained sections were visualized using a Zeiss Axiophot 2 photomicroscope (Zeiss, Göttingen, Germany) and a Nikon Eclipse 2000E confocol microscope (Nikon, Melville, NY).
We quantified Ly6G-positive neutrophils in four brain sections/animal in the region closely adjacent to the LPS injection site. Due to an uneven distribution of L6G-positive cells throughout different brain regions, we selected four areas per brain section using the 103 objective of a Zeiss Axiophot 2 photomicroscope. Ly6G positive cells were visualized and counted within the selected 103 field without the examiner's knowledge of genotype. We summed the number of Ly6G-positive cells from all four areas per section to obtain the total cell number/section. The total Ly6G-positive cell number per section was averaged and statistically compared between the p38a fl/fl and GFAP cre p38a 2/2 genotype. For microglia/macrophage quantification, we counted Iba1-positive cells present in the brain region near the LPS injection site. Iba1-positive cells were evenly distributed throughout the brain, thus, we counted cells from eight sections per animal adjacent to the LPS injection site. Quantification areas were selected in one area/ section under 103 magnification on a Zeiss Axiophot 2 photomicroscope and Iba1-positive cells were counted with the examiner blinded to genotype. We pooled the number of cells/region and obtained an average number of Iba1-positive cells/section for each mouse. Overall data was statistically compared between the p38a fl/fl and GFAP cre p38a 2/2 mice were viable with no phenotypic abnormalities. To study the specific role of p38a in astrocytes, we generated a conditional GFAP-specific p38a knockout mouse by crossing hGFAP-Cre [FVB-Tg(GFAP-cre)25Mes/J] mice with p38a-floxed [B6.129-Mapk14,tm1.2Otsu.] mice. The targeted disruption of p38a gene in GFAP cre p38a 2/2 mice is mediated by Cre-loxP recombination under the control of hGFAP promoter, and p38a gene deletion only occurred in specific cell types with an active hGFAP promoter as illustrated (Fig. 1A) . The resulting genotype of GFAP cre p38a 2/2 mice was detected by the presence of homozygous p38a-floxed alleles and being positive for hGFAP-Cre transgene (Fig. 1B) . The homozygous p38a fl/fl mice without hGFAP-Cre were indistinguishable from the GFAP cre p38a 2/2 littermates in phenotypic appearance, behavior, and body weights. Histological examination also did not show any astrocyte-specific developmental defects in the central nervous system. In addition to studying the in vivo effects of p38a in astrocytes during CNS inflammation, the generation of these mice also allowed us to establish p38a fl/fl and p38a 2/2 astrocyte cultures. Using these cultures, we could examine the immune activity of astrocytes in the absence of other immune cells and the complex inflammatory milieu seen in the in vivo CNS.
Pure astrocyte cultures could be established from both p38a 2/2 and p38a fl/fl astrocytes. We first generated astrocyte cultures using pups from cross breed of homozygous ROSA26-tdTomato(mT)-EGFP(mG) and hGFAP-Cre mice, in which, tdTomato gene is excised by Cre recombinase, leading to EGFP expression in cells with an active hGFAP promoter (Fig. 1C) . We then confirmed the purity of astrocyte cultures using this double fluorescent reporter cells in primary culture. After expansion of these cultures, we identified a confluent population of GFAP 1 astrocytes expressing EGFP that were predominant with no tdTomato positive cells indicating the absence of contaminating cell types that would include microglia, oligodendrocytes, and fibroblasts ( Fig 1D) . This protocol could be consistently reproduced and was used to derive highly pure populations of astrocytes that could be used for subsequent in vitro experiments. After astrocyte cultures were made from p38a fl/fl and GFAP cre p38a
2/2 mice, we also verified for the absence of p38a protein expression in p38a 2/2 cultures ( Fig 1E) .
Altered JNK, and ERK 1/2 signaling in IL-1b activated p38a
astrocytes. Cross talk between MAPK signalling pathways commonly occurs during cellular response to inflammatory stress. We examined whether p38a deficiency in astrocytes affects JNK and ERK1/2 activation in response to IL-1b stimulation. We observed an early phosphorylation of JNK and ERK1/2 proteins in both p38a fl/fl and p38a 2/2 astrocytes at 15 min after IL-1b treatment. This indicates that p38a deficiency in astrocytes has a minimal effect on initiating ERK1/2 and JNK signaling. Although phosphorylated ERK1/2 was not found in resting p38a 2/2 astrocytes, IL-1b stimulation resulted in a sustained ERK1/2 phosphorylation over time in both p38a fl/fl and p38a 2/2 astrocytes. Moreover, ERK1/2 phosphorylation remained at lower levels in p38a 2/2 astrocytes compared to p38a fl/fl controls. In contrast, we observed a relatively enhanced and sustained JNK activation in p38a 2/2 astrocytes indicated by increased phosphorylation levels over the entire duration of IL-1b exposure compared to an acute drop off of JNK phosphorylation in p38a fl/fl astrocytes ( Fig. 2A ). This suggests that the JNK pathway is highly activated by IL-1b in the absence of p38a signaling in astrocytes.
Reduced MK2 protein levels in p38a
2/2 astrocytes in response to LPS. Studies have shown that p38 MAPKs regulate inflammatory gene expression through an MK2-dependent AU-rich element (ARE)-containing mRNA stabilization mechanism 51 . We examined whether p38a deficiency has an effect on MK2 expression in astrocytes before and during immune activation using LPS. In this study, we observed that basal levels of MK2 protein in p38a 2/2 astrocytes were undetectable in a western blot compared to p38a fl/fl astrocytes (Fig. 2B) . In a time course, immune activation by LPS treatment did not induce MK2 expression in p38a 2/2 astrocytes. Basal levels of MK2 expression observed in p38a fl/fl astrocytes were also unaffected by LPS treatment. These data suggest that p38a deficiency has a negative effect on MK2 expression in astrocytes.
Diminished NF-kB activity in p38a
2/2 astrocytes in response to LPS. We next investigated whether p38a deficiency has an effect on the NF-kB activity in the p38a 2/2 or p38a fl/fl astrocytes after LPS stimulation. By immunoblot analysis, we observed that immune activation by LPS treatment did not induce phosphorylated IkB kinase (p-IKK) protein in p38a
2/2 astrocytes compared to p38a
fl/fl astrocytes ( Fig. 2C ). In the meanwhile, LPS treatment did not induce degradation of IkBa protein in p38a 2/2 astrocytes (Fig. 2C ). These data suggest that NF-kB is involved in p38a regulation of proinflammatory cytokine and chemokine expression in astrocytes.
LPS induces differential cytokine, chemokine and adhesion molecule expression in p38a
2/2 and p38a fl/fl astrocytes. We examined the production of different chemokines CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2 and CXCL10 in p38a
2/2 and p38a fl/fl astrocytes in response to LPS exposure. CCL2 and 2/2 astrocytes was examined with western blot analysis after IL-1b treatment. Exposure to IL-1b led to an acute and enhanced activation of JNK phosphorylation in p38a 2/2 compared to p38a fl/fl astrocytes. Although phosphorylated ERK1/2 was not found in resting p38a CXCL10 mRNA levels were significantly upregulated over time after LPS treatments in control p38a fl/fl astrocytes (p , 0.05). In contrast, a relatively moderate but significant change in CXCL10 expression was seen in p38a 2/2 astrocytes over time after LPS treatment (p , 0.05; Fig. 3G ), whereas a moderate but significant change of CCL2 expression was only detected in p38a 2/2 astrocytes at 6 hours after LPS treatment (p , 0.05; Fig. 3A) . However, this difference in trend of CCL2 and CXCL10 mRNA expression did not reach significance when statistically compared between the two genotypes. On the other hand, both CCL4 and CXCL1 mRNA levels were significantly upregulated in p38a fl/fl and p38a 2/2 astrocytes response to LPS exposure (p , 0.05). In particular, significantly lower expression of CCL4 was observed in p38a 2/2 astrocytes at 2, 4 and 6 hours after LPS treatment, compared to p38a fl/fl astrocytes (p , 0.05; Fig. 3C ). CXCL1 mRNA expression was significantly lower in p38a 2/2 astrocytes compared to p38a fl/fl astrocytes at 4 and 6 hours after LPS treatment (p , 0.05; Fig. 3E ). On a moderate scale, a significant upregulation of CCL3, CCL5, and CXCL2 mRNA expression was seen in both p38a
2/2 and p38a fl/fl astrocytes over time after LPS treatment (p , 0.05) with no difference between the genotypes for any of the time points (Fig. 3B, D and F) .
We then examined the expression of IL-6, IL-1b, TNFa, and COX-2 in p38a 2/2 and p38a fl/fl astrocytes after LPS treatment. Expression of IL-1b mRNA level was significantly upregulated and sustained throughout the duration of LPS treatment in both p38a
2/2 and p38a fl/fl astrocytes (p , 0.05; Fig. 3H ). We found no statistical differences between the two genotypes at any of the three time points for LPS treatment. A significant upregulation of IL-6 mRNA was observed in control p38a fl/fl astrocytes over time after LPS exposure (p , 0.05). Only a moderate but significant upregulation of IL-6 was seen in p38a 2/2 astrocytes over time after LPS treatment (p , 0.05). IL-6 mRNA expression was significantly lower in p38a 2/2 astrocytes compared to p38a fl/fl astrocytes at 4 hours after LPS treatment (p , 0.05; Fig. 3I ). There was significant upregulation of TNFa mRNA expression in both p38a 2/2 and p38a fl/fl astrocytes in response to LPS (p , 0.05). TNFa mRNA expression in p38a 2/2 astrocytes was significantly lower compared to p38a fl/fl astrocytes at 4 and 6 hours after LPS treatment (p , 0.05; Fig. 3J ). In response to LPS, there was a moderate upregulation of COX-2 mRNA seen in p38a fl/fl astrocytes, whereas no distinguishable change of COX-2 mRNA levels was observed in p38a 2/2 astrocytes. COX-2 mRNA expression was significantly lower in p38a 2/2 astrocytes compared to p38a fl/fl astrocytes at 4 and 6 hours after LPS treatment (p , 0.05; Fig. 3K ). This result suggests that p38a plays a predominant role in regulating IL-6, TNFa and COX-2 expression in LPS-stimulated astrocytes.
We also examined whether p38a regulates the induction of ICAM-1 and VCAM-1 in astrocytes after LPS exposure. ICAM-1 showed a trend of upregulation but did not reach statistical significance for both p38a fl/fl and p38a 2/2 astrocytes when compared at different time points after LPS exposure (Fig. 3L) . Similarly, for VCAM-1, we did not observe any significant differences in mRNA levels after LPS exposure (Fig. 3M) . We also did not detect any statistically significant differences for ICAM-1 and VCAM-1 expression levels between p38a 2/2 and p38a fl/fl astrocytes after LPS treatment.
Interleukin-1b induces differential cytokine, chemokine and adhesion molecule expression in p38a 2/2 and p38a fl/fl astrocytes. We examined the specific effects of IL-1b on the activation of chemokines CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2, and CXCL10 in p38a fl/fl and p38a 2/2 astrocytes. CCL2 and CXCL1 mRNA levels were significantly upregulated in both p38a fl/fl and p38a 2/2 astrocytes after IL-1b treatment (p , 0.05; Figure 4A and E). However, CCL2 expression was significantly lower in p38a 2/2 astrocytes at 6 hours compared to p38a fl/fl astrocytes after IL-1b treatment. (p , 0.05; Fig. 4A ). After an upregulation at time points 2 and 4 hours, CXCL1 mRNA levels dropped in both genotypes at 6 hours after IL-1b exposure; we found that this decrease in CXCL1 expression was significantly lower in p38a 2/2 astrocytes compared to p38a fl/fl astrocytes (p , 0.05; Fig. 4E ). A significant short-term upregulation of CXCL2 was detected in both p38a 2/2 and p38a fl/fl astrocytes after IL-1b treatment (p , 0.05). However, we detected that CXCL2 expression was significantly lower in p38a 2/2 astrocytes at time points 2, 4 and 6 hours after IL-1b exposure compared to p38a fl/fl astrocytes (p , 0.05; Fig. 4F ). CCL3 mRNA levels remained unchanged after IL-1b treatment in both p38a
2/2 and p38a fl/fl astrocytes (Fig. 4B) . Interestingly, we found significantly lower basal levels of CCL4 in p38a 2/2 and p38a fl/fl astrocytes. After IL-1b exposure, CCL4 appeared to be upregulated at 2 and 4 hours but was not statistically significant. Even after 2 hours of IL-1b treatment, CCL4 in p38a 2/2 astrocytes was significantly lower than p38a fl/fl astrocytes (p , 0.05; Fig. 4C ). A moderate but significant linear upregulation of CCL5 mRNA expression was seen in both p38a
2/2 and p38a fl/fl astrocytes over time after IL-1b treatment (p , 0.05). However, we did not detect significant differences between the genotypes for any of the time points (Fig. 4D ). CXCL10 expression showed a similar trend of upregulation but only reached statistical significance in both p38a fl/fl and p38a 2/2 astrocytes at 6 hours after IL-1b exposure compared to 0 hours (p , 0.05; Fig 4G) . We did not detect any statistically significant differences for CXCL10 expression levels between p38a
2/2 and p38a fl/fl astrocytes after IL-1b treatment (Fig. 4G) .
In addition to chemokines, we examined whether p38a has a regulatory effect on IL-1b-induced COX-2 activation in astrocytes. Our results showed no differences in COX-2 mRNA expression either temporal or between p38a 2/2 and p38a fl/fl astrocytes in response to IL-1b treatment (Fig. 4H) . We also examined for the activation of other inflammatory mediators such as TNFa and IL-6 in p38a fl/fl and p38a 2/2 astrocytes after IL-1b exposure. IL-6 mRNA levels were significantly upregulated after 2-, 4-and 6-hour IL-1b treatments in control p38a fl/fl astrocytes (p , 0.05). In contrast, no significant change in IL-6 expression was seen in p38a 2/2 astrocytes at these time points after IL-1b treatment. In particular, we detected a significantly lower expression of IL-6 in p38a 2/2 astrocytes at 2 and 6 hours after IL-1b exposure compared to p38a fl/fl astrocytes (p , 0.05; Fig. 4J ). We found no significant differences in TNFa mRNA expression over time or between p38a fl/fl and p38a 2/2 astrocytes in response to IL-1b exposure (Fig. 4I) .
We next examined for the effect of IL-1b treatment on ICAM-1 and VCAM-1 expression in astrocytes. We found moderate but significant upregulation of ICAM-1 in both p38a fl/fl and p38a 2/2 astrocytes over time after IL-1b treatment that peaked at 4 hours (p , 0.05). ICAM-1 levels in p38a 2/2 astrocytes at 2 hours after IL-1b treatment was significantly lower compared to p38a fl/fl astrocytes (p , 0.05; Fig. 4K) . Similarly, VCAM-1 showed a trend of upregulation for the entire duration of IL-1b exposure but did not reach statistical significance for both p38a fl/fl and p38a 2/2 astrocytes. We also did not observe any significant differences in VCAM-1 mRNA levels between genotypes at the three time points after IL-1b exposure (Fig. 4L) . These data suggest that p38a plays a crucial role during early induction of ICAM-1 in astrocytes after IL-1b exposure.
Interferon c induces differential cytokine, chemokine and adhesion molecule mRNA expression in p38a 2/2 and p38a fl/fl astrocytes. We examined whether IFNc-induced activation of astrocytes regulates CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2, and CXCL10 gene expression through the p38a signaling pathway.
Our results show that a significant upregulation of CCL2 mRNA expression was seen in p38a fl/fl astrocytes after IFNc treatment (p , 0.05), whereas in p38a 2/2 astrocytes a significant upregulation of CCL2 was detected only at 6 hours after IFNc treatment (p , 0.05; Fig 5A) . Similarly, CXCL10 mRNA levels were significantly upregulated after 2-, 4-and 6-hour IFNc treatments in control p38a fl/fl astrocytes (p , 0.05), whereas a relatively moderate but significant change in CXCL10 expression was seen in p38a 2/2 astrocytes only at 4 and 6 hours after IFNc treatment (p , 0.05; Fig 5G) . However, these trends of CCL2 and CXCL10 mRNA expression did not reach statistical significance when compared between the two genotypes ( Fig. 5A and G) . For CCL5, mRNA levels were significantly upregulated at 4 and 6 hours after IFNc treatment in control p38a
fl/fl astrocytes (p , 0.05), whereas no significant change was observed in p38a 2/2 astrocytes over time after IFNc treatment suggesting that CCL5 expression was refractory to IFNc treatment in p38a 2/2 astrocytes. Supporting this observation, statistics comparing p38a 2/2 astrocytes at 2, 4 and 6 hours to p38a
fl/fl astrocytes after IFNc exposure showed significant differences between the two genotypes (p , 0.05; Fig. 5D ). Similarly, CXCL1 expression increased significantly in p38a fl/fl astrocytes after IFNc treatment (p , 0.05), but only moderately significant fold-changes in the expression of CXCL1 were seen in p38a
2/2 astrocytes (p , 0.05). However, CXCL1 expression was significantly lower in Fig. 5E ). Fig. 5B and 5F ). Similar to trends observed for CCL3 and CXCL2, we found lower baseline expression of CCL4 in p38a 2/2 astrocytes and no observable upregulation in this genotype. Although there was upregulation of CCL4 in p38a fl/fl astrocytes after IFNc treatment, this difference did not reach statistical significance. Despite this general trend, we did not detect any statistically significant differences for CCL4 expression in comparisons between p38a 2/2 and p38a fl/fl astrocytes (Fig. 5C ). We also examined whether p38a regulates TNFa expression during an IFNc-induced astrocytic response. A moderate upregulation of TNFa was observed in p38a fl/fl astrocytes at 4 and 6 hours after IFNc exposure, whereas in p38a 2/2 astrocytes, TNFa expression continued to remain at baseline levels even at 2, 4 and 6 hours after IFNc treatment. However, this difference in trend of TNFa mRNA fold-change did not reach statistical significance when compared between the two genotypes (Fig. 5H) .
We next examined the role of p38a in regulating adhesion molecule expression in astrocytes induced by IFNc. We observed a moderate but significant upregulation of both ICAM-1 and VCAM-1 in p38a fl/fl and p38a 2/2 astrocytes response to IFNc exposure (p , 0.05). However, we noted significantly lower upregulation of ICAM-1 in p38a 2/2 astrocytes at 2 and 6 hours after IFNc treatment compared to p38a fl/fl astrocytes (p , 0.05; Fig. 5I ). Similarly, a significantly lower upregulation of VCAM-1 was seen in p38a 2/2 astrocytes at 2 and 4 hours after IFNc exposure compared to p38a fl/fl astrocytes (p , 0.05; Fig. 5J ). Overall, this data suggests that p38a plays an essential role in regulating CCL5, CXCL1, ICAM-1 and VCAM-1 activation in astrocytes exposed to IFNc treatment, while having a minimal effect on CCL2, CXCL10 and TNFa induction.
Intracerebral LPS injection induces differential cytokine, chemokine and adhesion molecule expression in GFAP cre p38a 2/2 mice. We examined the induction of several specific chemokines. CCL2, and CXCL10 mRNA levels were significantly upregulated in p38a fl/fl and GFAP cre p38a 2/2 mice at 6 and 12 hours after intracerebral LPS injection (p , 0.05). In comparison between the two genotypes, we found a significantly higher expression of CCL2 and CXCL10 in GFAP cre p38a
2/2 mice at 6 hours after LPS injection (p , 0.05; Fig. 6A and 6G ). For CCL3, a moderate but significant upregulation was observed in GFAP cre p38a
2/2 mice at 6 and 12 hours after intracerebral LPS injection (p , 0.05), while no observable changes of CCL3 were seen in p38a fl/fl cohorts at these time points. Therefore, levels of CCL3 were also significantly higher in GFAP cre p38a 2/2 mice at 6 and 12 hours after intracerebral LPS injection (p , 0.05; Fig. 6B ). Similarly, CXCL2 mRNA levels were significantly upregulated at 6 and 12 hours in GFAP cre p38a
2/2 mice after intracerebral LPS injection (p , 0.05). Although upregulation was moderate in p38a fl/fl cohorts it was also significant at 6 and 12 hours compared to 0 hours. Comparing CXCL2 expression between the two genotypes showed a significantly higher expression in GFAP cre p38a 2/2 mice at 6 and 12 hours compared to p38a fl/fl cohorts (p , 0.05; Fig. 6F ). For CCL4, significant upregulation was observed in both GFAP cre p38a
2/2 mice and p38a fl/fl mice after LPS injections at 6 and 12 hours. When expression levels were compared between the two genotypes, we found CCL4 expression to be significantly higher in GFAP cre p38a 2/2 mice at both 6 and 12 hours compared to p38a
fl/fl cohorts (p , 0.05; Fig. 6C ). Expression of CCL5 was significantly upregulated in both p38a fl/fl and GFAP cre p38a 2/2 mice in the time course (6 and 12 hours) after intracerebral LPS injection (p , 0.05). We found no statistical differences between the two genotypes for CCL5 at any of the three time points (Fig. 6D) . Similarly, expression of CXCL1 was significantly upregulated in both p38a fl/fl and GFAP cre p38a 2/2 mice at 6 and 12 hours after intracerebral LPS injection (p , 0.05); we detected no statistically significant differences in CXCL1 levels between the genotypes (Fig. 6E) .
In addition to chemokines, we also examined the expression of TNFa, IL-6, and IL-1b in p38a fl/fl and GFAP cre p38a 2/2 mice after intracerebral LPS injections. We found a moderate but significant upregulation of TNFa mRNA in GFAP cre p38a 2/2 mice at 12 hours after intracerebral LPS injection (p , 0.05), whereas no observable upregulation of TNFa mRNA level were detected in p38a fl/fl cohorts over time after LPS injection. Differences were significant with higher fold-change in GFAP cre p38a
2/2 mice compared to p38a fl/fl cohorts at 6 and 12 hours after LPS injections (p , 0.05; Fig. 6H ).
We observed significant upregulation of IL-6 in both p38a fl/fl and GFAP cre p38a 2/2 mice over time after LPS injection (p , 0.05). Although no differences were observed between genotypes at the peak of IL-6 expression at 12 hours after LPS injection, a significantly higher expression of IL-6 was detected in GFAP cre p38a
2/2 mice at 24 hours after LPS injection, compared to p38a fl/fl cohorts (p , 0.05; Fig. 6I ). On the other hand, IL-1b mRNA levels were significantly upregulated in GFAP cre p38a 2/2 mice over time after LPS injection (p , 0.05). In contrast, a relatively moderate change in IL-1b expression was seen in p38a fl/fl cohorts at 6 and 12 hours after LPS injection (p , 0.05). In particular, a significantly higher expression of IL-1b was observed in GFAP cre p38a
2/2 mice at 6 and 12 hours after LPS injection, compared to p38a fl/fl cohorts (p , 0.05; Fig. 6J ). In vivo evidence indicated that systemic LPS injection stimulates COX-2 production within the CNS microvaculature 52 . We thus examined the COX-2 expression in p38a fl/fl and GFAP cre p38a 2/2 mice following intracerebral LPS injection. A significant upregulation of COX-2 mRNA was observed in GFAP cre p38a
2/2 mice at 6 and 12 hours after LPS injection (p , 0.05), while a moderate but significant upregulation of COX-2 was seen in p38a fl/fl cohorts over time after LPS injection (p , 0.05). In particular, we observed a significantly higher COX-2 mRNA expression in GFAP cre p38a
2/2 mice at 6 and 12 hours after LPS injection, compared to p38a fl/fl cohorts (p , 0.05; Fig. 6K ). Interestingly, COX-2 expression levels returned to baseline at 24 hours in the GFAP cre p38a 2/2 mice, and were significantly lower compared to p38a fl/fl cohorts at this time point (p , 0.05). Moreover, ICAM-1 and VCAM-1 are crucial adhesion molecules expressed by cellular components of CNS microvasculature including perivascular astrocytes 53 . Therefore, we examined the induction of VCAM-1 and ICAM-1 in p38a fl/fl and GFAP cre p38a 2/2 mice following intracerebral LPS injection. ICAM-1 mRNA levels were significantly upregulated in p38a fl/fl and GFAP cre p38a 2/2 mice at 12 and 24 hours after intracerebral LPS injection (p , 0.05). Particularly, in comparison with p38a fl/fl cohorts, a significantly higher expression of ICAM-1 was observed in GFAP cre p38a 2/2 mice at 12 and 24 hours after LPS injection (p , 0.05; Fig. 6L ). In contrast, a significant upregulation of VCAM-1 mRNA expression was seen in both p38a fl/fl and GFAP cre p38a 2/2 mice over time and peaked at 6 hours after intracerebral LPS injection (p , 0.05). However, we did not detect significant differences of VCAM-1 levels between the genotypes for any of the time points after LPS injection (Fig. 6M) . Therefore, astrocyte p38a signaling modulates in vivo ICAM-1 expression but not VCAM-1 expression during an intracerebral LPS challenge. Taken together, in vivo findings identified significantly higher expression of specific subsets of chemokines, cytokines, and adhesion molecules in the CNS of GFAP cre p38a 2/2 mice challenged with intracerebral LPS injection.
To corroborate these results based on mRNA levels using an alternative approach by immunohistochemical analysis of cytokine and chemokine expression, we performed and verified the immuno- reactivity of CCL2, CXCL10 and IL-6 in the increased population of CD681 cells in the brain of GFAP cre p38a 2/2 mice compared to p38a fl/fl mice at 6 hours after LPS challenge (Fig. 7A) . Quantification of immunoreactive cells expressing CCL2, CXCL10 and IL-6 showed the increased expression of CCL2, CXCL10 and IL-6 and particularly their expression in the increased population of CD681 cells in the brain of GFAP cre p38a 2/2 mice compared to p38a fl/fl mice after LPS stimulation (Fig. 7B) .
Reduced astrocyte activation in GFAP cre p38a 2/2 mice after intracerebral LPS injection. After an intracerebral LPS injection, we measured astrogliosis at the site of injection both indirectly by using astrocyte-specific mRNA responses and directly by immunohistochemical and histomorphological examination of astrocyte responses. At 12 and 24 hours after injections, we observed a significant upregulation of GFAP in both p38a fl/fl and GFAP cre p38a 2/2 mice (p , 0.05). However, the increases in GFAP mRNA in GFAP cre p38a 2/2 mice were significantly lower compared to p38a fl/fl cohorts at 24 hours after intracerebral LPS injection (p , 0.05; Fig. 8A ). This was consistent with in vitro findings in which p38a 2/2 astrocytes exhibited a relatively lower expression of inflammatory genes after LPS, IL-1b or IFNc exposure. Supporting the qPCR data, immunohistopathology evidence also identified clear signs of reactive astrogliosis with associated microglia/macrophages in both GFAP cre p38a 2/2 and p38a fl/fl mice 24 hours after LPS injection (Fig. 8B) . However, the region of astrocyte activation and the entire dimensions of the lesion were markedly reduced in GFAP cre p38a
2/2 mice. In p38a fl/fl mice, we observed a dense population of GFAP-immunoreactive astrocytes with a characteristic morphology indicative of activation at the site of injection in the brain cortex. In GFAP cre p38a
2/2 mice, the pathology was markedly less. These findings provide a second line of evidence indicating that astrocytes deficient in p38a are less responsive to inflammatory injury.
Enhanced neutrophil infiltration in GFAP cre p38a 2/2 mice after intracerebral LPS injection. To investigate the cellular source of upregulated chemokines and cytokines in GFAP cre p38a
2/2 mice, we examined the presence and expression levels of Ly6G mRNA following intracerebral LPS injections. A significant upregulation of Ly6G mRNA was observed in GFAP cre p38a
2/2 mice at 6 and 12 hours after intracerebral LPS injection (p , 0.05), while no observable upregulation of Ly6G was seen in p38a fl/fl cohorts over time. In comparisons between the two genotypes, we detected a significantly higher expression of Ly6G mRNA in GFAP cre p38a 2/2 mice at 6 hours after LPS injection compared to p38a fl/fl cohorts (p , 0.05; Fig. 9A ). After the initial increase at 6 hours, Ly6G mRNA expression returned to near-baseline levels at 12 hours post-LPS injection. This suggests an acute infiltration of neutrophils occurred at the CNS of GFAP cre p38a
2/2 mice in response to an intracerebral LPS exposure. Supporting the qPCR data, immunocytochemistry evidence also identified a massive infiltration of neutrophils existing in both GFAP cre p38a 2/2 and p38a fl/fl mice 24 hours after LPS injection (Fig. 9B) . In particular, accumulation of Ly6G positive neutrophils surrounding the needle tract region was apparent in both p38a fl/fl and GFAP cre p38a 2/2 mice. We observed a high density of Ly6G positive neutrophils at the perivascular space of the brain parenchyma in both p38a fl/fl and GFAP cre p38a 2/2 mice. In contrast, the distribution of Ly6G positive neutrophils was dispersed at the cortical region of p38a fl/fl and GFAP cre p38a 2/2 mice. Quantification of neutrophil infiltrates revealed a significantly increased number of Ly6G positive neutrophils present at the CNS of GFAP cre p38a
2/2 mice 24 hours post-LPS injection, compared to p38a fl/fl cohorts (p , 0.01; Fig. 8C ). Together these data provide strong evidence that there is significantly higher infiltration of neutrophils in the CNS of GFAP cre p38a 2/2 mice after intracerebral LPS injection, compared to p38a fl/fl cohorts.
Increased microglia/macrophage presence in GFAP cre p38a
2/2 mice after intracerebral LPS injection. Using CD11b and CD68 as specific markers for macrophages/microglia, we examined the inflammation site after intracerebral LPS injection in p38a fl/fl and GFAP cre p38a 2/2 mice. A significant upregulation of CD11b and CD68 mRNA was observed in GFAP cre p38a 2/2 mice that increased with time and peaked at 12 hours after intracerebral LPS injection (p , 0.05); a relatively moderate but also significant upregulation of CD11b and CD68 was also seen in the p38a fl/fl cohorts after LPS injection (p , 0.05). Interestingly, this upregulation of CD11b in www.nature.com/scientificreports GFAP cre p38a 2/2 mice was significantly higher than that observed in control p38a fl/fl mice at 6 hours after LPS injection (p , 0.05; Fig. 10A ). However, while the CD11b expression level for both genotypes dropped down at 24 hours after LPS injection, we observed significantly lower CD11b levels in GFAP cre p38a 2/2 mice at this time point, compared to p38a fl/fl cohorts (p , 0.05; Fig. 10A ). Corresponding with the expression pattern of CD11b, significantly higher expression levels of CD68 was observed in GFAP cre p38a 2/2 mice at 6 and 12 hours after LPS injection, compared to p38a fl/fl cohorts (p , 0.05; Fig. 10B ). This observation corroborated that both primer sets accurately identified a specific cell type. Taken together, increased upregulation of CD11b and CD68 indicates either a more prominent CNS microglial proliferation and/or a greater number of macrophage infiltrations in the brain of GFAP cre p38a
2/2 mice. To examine the specific tissue pathologies associated with intracerebral LPS injections, we performed immunohistochemistry for Iba1-positive macrophages/microglia in the CNS of both GFAP cre p38a 2/2 and p38a fl/fl mice. Massive concentrations of macrophages/microglia were found present at the injection site in both p38a
fl/fl and GFAP cre p38a 2/2 mice www.nature.com/scientificreports (Fig. 10C) . Quantification of Iba1 positive cells in this immunopathology revealed that significantly higher number of macrophages/microglia were present in the brain parenchyma of mice highlight an important facet for p38a signaling in CNS inflammation.
In addition to neutrophil and macrophages/microglia, we investigated whether intracerebral LPS injection promoted T lymphocyte recruitment in the CNS parenchyma of GFAP cre p38a 2/2 and p38a fl/fl mice. We examined the expression levels of CD4 and CD8 to identify T lymphocytes. We found no significant upregulation of CD4 or CD8 in both GFAP cre p38a 2/2 and p38a fl/fl mice, compared to the non-injection p38a fl/fl cohorts.
Discussion
Signaling via the p38a pathway is essential for immune response in multiple cell types. As global p38a knockout mice show embryonic mortality 54, 55 , the role of p38a in cell type specific responses in vivo has not been characterized. By generating conditional knockout mice, we sought to examine astrocyte-specific immune responses mediated by the p38a pathway. We revealed a critical role of p38a in the regulation of immunological responses and the production of specific cytokines and chemokines, and a rather complex role of astrocytes in immune regulation in the CNS. First, by isolating astrocyte-specific responses in vitro, we identified that p38a pathway critically regulates different cytokines: TNFa and IL-6, and chemokines: CCL2, CCL4, CXCL1, CXCL2 and CXCL10. By interpreting this information through what is known about the different cytokine and chemokine regulation, we believe that this regulation by the p38a pathway is by affecting multiple targets. It has been suggested that expression of CCL2, CXCL10 and IL-6 is via a NFkB-dependent mechanism [56] [57] [58] . In dendritic cells, it has been shown that p38 a activity is required at a very fundamental level for the phosphorylation and phosphoacetylation of histone H3 on a subset of cytokine and chemokine gene promoters in order to enhance accessibility to NFkB binding sites 59, 60 . We found that p38a 2/2 astrocytes are refractory to LPS treatment in vitro and there is a direct regulation of CCL2, CXCL10 and IL-6 by p38a signaling. The regulation of NFkB by p38a signaling in astrocytes would also induce secondary responses affecting multiple other effectors and adding to the complexity of the overall response. Other inflammatory mediators like CCL3, CCL4, CCL5, IL-1b and VCAM-1, also regulated at least in part by NFkB in different cell types [61] [62] [63] [64] . CCL3, CCL5 and VCAM-1 induction was significantly lower in p38a 2/2 astrocytes after IFNc treatment, but induction was not different from p38a fl/fl astrocytes after treatment with LPS or IL-1b. Similarly, CCL4 induction was significantly lower in p38a 2/2 astrocytes after treatment with LPS or IL-1b, but induction was not different from p38a fl/fl astrocytes after treatment with IFNc. Although these specific effects provide direct clues to regulation of p38a signaling in astrocytes, deciphering the mechanisms underlying these observations is complicated by crosstalk between p38a and other immune-mediated signaling pathways that may result in different transcriptional responses.
Several reports have highlighted potential crosstalk between p38a, JNK and ERK1/2 pathways in many cell types 65, 66 . p38a and JNK share an upstream kinase MKK4; in cancer cells, p38a deficiency has been suggested to cause MKK4 to shift its kinase activity toward JNK activation 67 . In astrocytes, we found that JNK activation is enhanced in p38a 2/2 astrocytes, suggesting an aberrant effect in this pathway. JNK regulates c-Jun phosphorylation that is required for AP-1 transcriptional activation and gene expression [68] [69] [70] . It is known that overexpression of AP-1 induces ICAM-1and CCL2 up-regulation 71 , and that both JNK and c-Jun are required for CCL2 expression 72 .
Findings from this study showed that up-regulation of ICAM-1 and CCL2 was not completely refractory in p38a 2/2 astrocytes, suggesting a potential compensation due to enhanced JNK activation. Downstream effects of this crosstalk can be explained by the convergence of signaling leading to NFkB regulation.
When examining direct downstream targets of p38a upstream of NFkB, we detected a significantly lower expression of MK2 protein expression in p38a 2/2 astrocytes. MK2 and MK3 are major protein kinases directly downstream of p38 MAPKs 35 , and studies have shown that p38a signaling is critical for cytokine-induced mRNA stabilization via MK2 and an AU-rich element (ARE) -targeted mechanism 51 . MK2 has been implicated in phosphorylation of ARE-binding proteins 73 , and a subsequent p38 MAPK-dependent stabilization of ARE is required for transcriptional activation of several inflammatory genes including IL-6, COX-2, TNFa and CXCL2 51, [74] [75] [76] . Similar results have been reproduced in several other studies that demonstrate a direct link between MK2-mediated phosphorylation and the transcription of IL-6, TNFa and CXCL1 [77] [78] [79] [80] . In support of regulation mediated by MK2 downstream of p38a signaling, findings in this study showed significant down-regulation of TNFa, IL-6, CXCL1, CXCL2 and COX-2 in p38a 2/2 astrocytes in response to different inflammatory stimuli. Taking another step in dissecting the role of p38a signaling in this response, we identified that LPS, IL-1b or IFNc treatment all lead to a similar downregulation of CXCL1 in p38a 2/2 astrocytes. This convergence between IFNc receptor, IL-1 receptor and toll-like receptor triggered events suggests a possible role of a common adaptor element like MyD88; p38a and MK2 have been shown to be required for MyD88-mediated ARE-containing mRNA activation during chemokine expression 81 . Previous studies have demonstrated that MyD88 is an essential adaptor to transduce signaling cascades relayed from IFNc receptor 81 , IL-1 receptor
82
, and the toll-like receptor 4 activity 83 . Findings in this study using p38a 2/2 astrocytes recapitulated and validated this mechanism of regulation for CXCL1.
For further understanding of astrocyte regulation of immune function, we also examined the role of astrocyte p38a signaling in a more complex neuroinflammation context in vivo. Due to reduced expression of inflammatory genes observed in p38a 2/2 astrocytes in vitro, we originally anticipated similar outcomes from the intracerebral LPS injection model in GFAP cre p38a
2/2 mice. Unexpectedly, we found that the induction of chemokines: CCL2, CCL3, CCL4, CXCL2 and CXCL10, and cytokines: TNFa, IL-6 and IL-1b, and ICAM-1 were significantly higher in the CNS of GFAP cre p38a 2/2 mice compared to p38a fl/fl cohorts. Investigating the underlying reasons for this discrepancy revealed that GFAP cre p38a 2/2 mice had significantly higher numbers of microglia and infiltrates like macrophages and neutrophils at the site of injury. Presence of these immune cells that were identified by specific markers Ly6G, CD11b and CD68 was correlated with the increased levels of cytokines and chemokines.
Many in vivo studies have suggested that neutrophils represent a significant source of chemokines such as CCL3, CCL4, CXCL1, CXCL8, and CXCL10 84, 85 , which in turn chemoattract monocytes, dendritic cells, T lymphocytes and more neutrophils 23, 86 . Therefore, neutrophils play a significant role in recruiting infiltrates at sites of CNS inflammation. Findings in this study indicated that GFAP cre p38a
2/2 mice undergo acute and massive infiltration of neutrophils in response to CNS immune injury. This infiltration could be a cellular source that leads to significant up-regulation of CCL3, CCL4 and CXCL10 highlighting an important secondary effect due to the deficiency of p38a signaling in astrocytes. Perhaps as part of this neutrophil effect or an independent regulation, GFAP cre p38a 2/2 mice develop a more prominent CNS microglia/macrophage response. Even though there are no markers to distinguish activation of resident microglia and the infiltrating macrophage populations, this observation reveals a clear difference of microglial/macrophage response in GFAP cre p38a 2/2 mice in response to LPS. In vitro studies have shown that microglia/macrophages can produce TNFa and IL1b in response to LPS stimulation 87 . Previous studies have also shown that microglia can produce CCL2, CCL3, CCL4, CCL5 and CXCL10 13, 14, 88, 89 , and macrophages can produce CCL2, CXCL1, CXCL8 90 , in response to in vitro TNFa exposure. Therefore, increased microglial/macrophage activation observed in GFAP cre p38a 2/2 www.nature.com/scientificreports mice could also contribute to the elevated levels of different cytokines and chemokines, adding to effects brought about by increased neutrophil infiltration.
We also observed a significant up-regulation of ICAM-1 in the CNS of GFAP cre p38a 2/2 mice after LPS injections. It is well documented that interaction between ICAM-1 and b2 integrin CD11b/ CD18 (MAC-1) is important for leukocyte transmigration at CNS inflammation sites 91, 92 . This provides indirect evidence that there is a concurrent increase in macrophage infiltration in GFAP cre p38a 2/2 CNS in addition to neutrophils, rather than a singular effect brought about by microglia. Altogether, our findings indicate that the deficiency of p38a attenuates an astrocytic response in vitro and results in an exacerbated CNS inflammatory response in vivo.
We directly examined astrocyte activation or ''reactive astrogliosis'' in vivo and showed an increase in GFAP expression both at the mRNA level and by immunohistopathology, suggesting that astrocytes in GFAP cre p38a
2/2 mice were less responsive to inflammatory stress. This attenuation of astrocyte activity due to the deficiency of p38a interestingly led to robust neutrophil and microglial/macrophage recruitment to the site of CNS injury. In addition to providing significant insight into the specific role of p38a signaling in astrocyte activation during CNS inflammation, these findings show direct evidence that reactive astrocytes have a protective role restricting inflammation in the CNS.
We observed reduced inflammatory gene expression in p38a mice after intracerebral LPS injection compared to p38a fl/fl cohorts in vivo. Owing to the complexity of in vivo CNS inflammatory milieu, the source of upregulated proinflammatory cytokines, chemokines and adhesion molecules could be derived from multiple cellular components other than p38a 2/2 astrocytes in the CNS of GFAP cre p38a
2/2 mice. We found crucial evidence demonstrating a significantly increased expression of infiltrating cell markers such as Ly6G, CD11b and CD68 in the CNS of GFAP cre p38a
2/2 mice, compared to p38a fl/fl cohorts, indicating that in vivo p38a 2/2 astrocytes with attenuated immune reactivity lost the capacity to maintain an intact astroglial barrier and thus result in an exacerbated permeability for leukocyte extravasation in the CNS parenchyma of GFAP cre p38a
2/2 mice. In accordance with attenuated astrogliosis of p38a 2/2 astrocytes in vivo, a paralleled upregulation between infiltrating cell markers and subsets of specific chemokines and cytokines in GFAP cre p38a 2/2 mice together confirmed that resident microglia, infiltrating neutrophils and macrophages are rather the major contributors of significantly upregulated proinflammatory cytokines and chemokines in the CNS of GFAP cre p38a
2/2 mice. Our data demonstrates a significantly increased expression of neutrophil marker Ly6G paralleled with significant upregulation of CCL3, CCL4 and CXCL10 in the CNS parenchyma of GFAP cre p38a 2/2 mice at identical time points after LPS injection, this suggests the cellular source of significantly upregulated CCL3, CCL4 and CXCL10 transcripts may be mainly derived from infiltrating neutrophils, rather than p38a 2/2 astrocytes in the CNS of GFAP cre p38a 2/2 mice. Following neutrophil invasion, macrophages and lymphocytes are the next infiltrating cell types recruited by the chemokines secreted from neutrophils or CNS resident cell types. A significantly increased amount of macrophage/ microglia in the CNS parenchyma of GFAP cre p38a 2/2 mice suggests either a more prominent CNS microglial proliferation or enhanced macrophage recruitment after intracerebral LPS injection. Thus, an elevated number of macrophages/microglia in the CNS of GFAP cre p38a
2/2 mice may contribute to an increased upregulation of chemokines CCL2, CCL3, CCL4, CXCL10, and cytokine TNFa observed in GFAP cre p38a
2/2 mice after LPS injection. Moreover, upregulation of ICAM-1 and CD11b in the CNS of GFAP cre p38a 2/2 mice both peaked at 12 hours following intracerebral LPS injection. Interaction between ICAM-1 and b2 integrin CD11b/CD18 (MAC-1) is considered as an important component for leukocyte transmigration at CNS inflammation sites, suggesting that ICAM-1 upregulation has an indispensable role in an increased accumulation of CD11b 1 macrophages/microglia in the CNS parenchyma of GFAP cre p38a
2/2 mice. Particularly, a significant upregulation of CD11b and CD68 in the CNS of GFAP cre p38a
2/2 mice may be partially derived from an additional recruitment of peripheral macrophages facilitated by an increased ICAM-1 expression.
Overall, we demonstrated consistency between in vitro and in vivo results in that astrocytes with p38a ablation are less reactive to inflammatory stimuli under both conditions. An attenuated immune reactivity of p38a 2/2 astrocytes in vivo specifically indicates the relevance between diminished reactive astrogliosis and impaired astroglial barrier in the CNS of GFAP cre p38a
2/2 mice. Meanwhile, in accordance with significantly increased Ly6G, CD68, and CD11b expression in the CNS of GFAP cre p38a 2/2 mice, a contrasting result emerged between in vitro and in vivo inflammatory gene expression level together confirmed that microglia, infiltrating neutrophils and macrophages act as major contributors to those significantly upregulated cytokine and chemokine mRNAs in the CNS of GFAP cre p38a 2/2 mice, rather than in vivo p38a 2/2 astrocytes with less immune reactivity. Particularly, the phenomenon of significantly increased immune infiltrates in the brain parenchyma of GFAP cre p38a
2/2 mice strongly suggests that the capacity of astrocytes in maintaining the CNS microvasculature barrier may be impaired due to p38a deficiency. On the other hand, this indicates that astrocyte p38a signaling may perform a more profound effect on regulating CNS microvasculature, rather than modulating immunological events under in vivo CNS inflammatory conditions.
We generated the conditional GFAP-specific p38a knockout mouse in order to study the definitive role of astrocyte p38a signaling under in vivo CNS inflammatory conditions. However, neurons derived from the neuroectoderm lineage underwent a GFAPexpression stage and have also been conditionally knocked-out of p38a during early neurogenesis 93 . Moreover, adult neurogenesis has been suggested to be mainly derived from GFAP-expressing progenitor cells 94, 95 . Thus, there exists a p38a 2/2 neuron population in addition to p38a 2/2 astrocytes in the CNS of these GFAP cre p38a 2/2 mice. During in vitro studies, the process of generating pure astrocyte cultures eliminated the p38a 2/2 neurons and p38a 2/2 neural progenitor cells through a sequential procedure of mechanical dislodgement, trypsinization and L-leucine methyl ester hydrochloride treatment. Therefore, a very minimal existence of p38a 2/2 neurons does not interfere with the in vitro immune activity of p38a 2/2 astrocytes in response to inflammatory stimulation. However, an inevitable existence of p38a 2/2 neurons in the CNS of GFAP cre p38a 2/2 mice might exhibit an additional effect on the in vivo CNS inflammatory response. Therefore, the existence of p38a deficient neurons and their response to LPS injection should also be considered as a potential factor contributing to the increased chemokine and cytokine upregulation in GFAP cre p38a 2/2 mice in response to LPSmediated inflammatory insults. Thus, neurons have the capacity to respond to an inflammatory stress via p38 MAPK signaling pathways and neurons with p38a ablation could be less vulnerable in response to inflammatory exposure in vivo. In our GFAP cre p38a 2/2 mouse model, neurons with p38a deficiency being less responsive to LPSinduced inflammatory stress may reduce its production of cytotoxic signal molecules, leading to an attenuated astroglial reactivity under conditions of in vivo CNS inflammation. Taken together, an attenuated reactive astrogliosis in vivo due to either astrocyte or neuronal p38a deficiency may contribute to an impaired astroglial barrier at the CNS perivascular space, and consequently result in a massive leukocyte infiltration in the brain parenchyma of GFAP cre p38a 2/2 mice following intracerebral LPS injection.
www.nature.com/scientificreports
In conclusion, we identified a specific role of p38a in regulating specific subsets of inflammatory genes during an astrocytic immune response, and that astrocytes with p38a ablation are less responsive to inflammatory stress under both in vivo and in vitro conditions. Under CNS inflammatory conditions, a diminished reactivity of astrogliosis in GFAP cre p38a
2/2 mice is suggested to impair the formation of astroglial barrier and abolish the effect on restricting leukocyte infiltration. Taken together, our findings reveal the significance of in vivo astrocyte p38a signaling in maintaining the barrier of CNS microcirculation, which is more crucial than modulating immunological events under CNS pathological conditions. Overall, this study not only highlights the importance of p38a signaling in astrocyte immune activation in vitro, but also provides mechanistic insight into understanding the cell-specific p38a signaling in the cellular components of neurovascular unit during CNS neuroinflammation. By investigating astrocyte function using the GFAP cre p38a
2/2 mouse model, we resolve a long-existing controversy in the field regarding the outcome of astrocyte activation by providing direct evidence that reactive astrogliosis restricts the severity of inflammation in the injured CNS.
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